‘de Novo’ repurposing of Daflon as anti-intestinal parasitic drug in experimental giardiasis

Fahmy, Azza; Abuelenain, Gehan; Rasheed, Nesma; Abdou, Amr M.

doi:10.1016/j.exppara.2021.108124

Cited by 3 publications

(3 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a controlled experiment, Daflon, a natural product used as a nutrient supplement and an antidiabetic drug, was evaluated alone or in combination with metronidazole in mice infected with Giardia. The findings demonstrated the efficacy of Daflon [ 117 ]. Drinic et al [ 118 ] reported the utilization of 14 compounds isolated from seven classes.…”

Section: New Compoundsmentioning

confidence: 89%

Ultrastructural Alterations of the Human Pathogen Giardia intestinalis after Drug Treatment

2023

View full text Add to dashboard Cite

This review presents the main cell characteristics altered after in vitro incubation of the parasite with commercial drugs used to treat the disease caused by Giardia intestinalis. This important intestinal parasite primarily causes diarrhea in children. Metronidazole and albendazole are the primary compounds used in therapy against Giardia intestinalis. However, they provoke significant side effects, and some strains have developed resistance to metronidazole. Benzimidazole carbamates, such as albendazole and mebendazole, have shown the best activity against Giardia. Despite their in vitro efficacy, clinical treatment with benzimidazoles has yielded conflicting results, demonstrating lower cure rates. Recently, nitazoxanide has been suggested as an alternative to these drugs. Therefore, to enhance the quality of chemotherapy against this parasite, it is important to invest in developing other compounds that can interfere with key steps of metabolic pathways or cell structures and organelles. For example, Giardia exhibits a unique cell structure called the ventral disc, which is crucial for host adhesion and pathogenicity. Thus, drugs that can disrupt the adhesion process hold promise for future therapy against Giardia. Additionally, this review discusses new drugs and strategies that can be employed, as well as suggestions for developing novel drugs to control the infection caused by this parasite.

show abstract

Section: New Compoundsmentioning

confidence: 89%

Ultrastructural Alterations of the Human Pathogen Giardia intestinalis after Drug Treatment

2023

View full text Add to dashboard Cite

show abstract

“…30,32 In our lab, researchers are dedicating their efforts to discovering phytochemicals or repurposing drugs that can be affordable and feasible for curing such challenging diseases. 18,33,34 On the one hand, this study aimed to mimic various human health conditions (immunocompetent and immunocompromised) when uptaking FA (spice), SP (antibiotic), or their combination in coincident and precedent to the infection with T. gondii. Hence, immune suppression with DMS was induced at different intervals, and three batches were investigated for the therapeutic effects of the candidate drugs at the latent stage.…”

Section: Discussionmentioning

confidence: 99%

“…Many drugs have been clinically tried to cure latent toxoplasmosis with no effect or poor tolerance 30,32 . In our lab, researchers are dedicating their efforts to discovering phytochemicals or repurposing drugs that can be affordable and feasible for curing such challenging diseases 18,33,34 …”

Section: Discussionmentioning

confidence: 99%

A multimodality therapeutic application on Toxoplasma gondii encephalitis utilizing Spiramycin and ‘de novo’ Ferula asafetida in immunodeficient mice

Almurshidi,

Fahmy,

El‐Shennawy

et al. 2023

Parasite Immunology

Self Cite

View full text Add to dashboard Cite

This study investigated a ‘de Novo’ medicinal herb, Ferula asafetida (FA), against toxoplasma encephalitis either alone or combined with spiramycin (SP). Female Swiss‐Webster mice (n = 72) were divided into three batches. Batch‐I received no DMS to serve as an immunocompetent control, batch‐II was immune‐suppressed with the DMS (0.25 mg/g/day) for 14 days pre‐infection, whilst batch‐III was immune‐suppressed with the DMS on the same day of infection. All experimental mice were inoculated with Toxoplasma gondii ME49 cysts (n = 75). Each batch was split into four subgroups: Mono‐SP, mono‐FA, combined drug (SP + FA), or neither. Therapies were administered on day zero of infection in batches (I and II) and 35 days post‐infection in batch (III). Treatments lasted for 14 days, and mice were sacrificed 60 days post‐infection. Histopathological changes, cysts load, and CD4 and CD8 T‐cells were counted in brain tissues. The cyst‐load count in mice receiving SP + FA was significantly (p < .0001) the least compared to the mono treatments in all protocols. Interestingly, the combined therapy demolished the T‐cell subsets to zero in immunocompetent and immunocompromised infected mice. In conclusion, F. asafetida might be a powerfully natural, safe vehicle of SP in the digestive system and/or across the brain–blood barrier to control toxoplasmosis even through immunodeficient conditions.

show abstract

Potential anti-schistosomal effect of Daflon, a repurposed drug targeting different stages of Schistosome maturity

El Skhawy,

Diab,

Hassan

et al. 2024

Parasitol Res

View full text Add to dashboard Cite

‘de Novo’ repurposing of Daflon as anti-intestinal parasitic drug in experimental giardiasis

Cited by 3 publications

References 82 publications

Ultrastructural Alterations of the Human Pathogen Giardia intestinalis after Drug Treatment

Ultrastructural Alterations of the Human Pathogen Giardia intestinalis after Drug Treatment

A multimodality therapeutic application on Toxoplasma gondii encephalitis utilizing Spiramycin and ‘de novo’ Ferula asafetida in immunodeficient mice

Potential anti-schistosomal effect of Daflon, a repurposed drug targeting different stages of Schistosome maturity

Contact Info

Product

Resources

About